Search bioRxiv⌕ Search

bioRxiv · 10.1101/441691

Stochastic simulations show how passive immunization can influence the germinal centre reaction and optimize host humoral responses

Abstract

Passive immunization with antigen-specific antibodies was shown recently to induce lasting improvements in endogenous antibody production, raising the prospect of using passive immunization as a tool to engineer host humoral responses. The mechanism with which administered antibodies alter endogenous antibody production remains unknown. B cells that produce antigen-specific antibodies evolve and get selected in germinal centres (GCs). This selection requires that B cells acquire antigen presented in GCs. We hypothesized that passive immunization biases this selection in favour of B cells with high affinities for antigen. Administered antibodies form immune complexes with antigen which only B cells with higher affinities than the administered antibodies for antigen can rupture and acquire antigen, thus increasing the selection stringency in GCs. With this mechanistic hypothesis, we constructed a stochastic simulation model of the GC reaction. The simulations recapitulated and synthesized several independent experimental observations, presenting strong evidence in support of our hypothesis. Further, the simulations revealed a quality-quantity trade-off constraining the GC response. As the selection stringency increased, surviving B cells had higher affinities for antigen but fewer B cells survived. Increasing antigen availability in the GC relaxed this constraint. The affinity of the administered antibodies and/or antigen availability could thus be tuned to maximize the GC output. Comprehensively spanning parameter space, we predict passive immunization protocols that exploit the quality-quantity trade-off and maximize the GC output. Our study thus presents a new conceptual understanding of the GC reaction and a computational framework for the rational optimization of passive immunization strategies.\n\nSignificance statementWhen natural antibody production is inadequate, passive immunization with external antibodies can alleviate disease. Remarkably, passive immunization induced lasting improvements in natural antibody production in recent studies, suggesting that it could be deployed to engineer natural antibody responses. However, how administered antibodies alter natural antibody production remains unknown. B cells that produce antibodies targeting specific antigen evolve in germinal centres (GCs). We hypothesized that administered antibodies form complexes with antigen, preferentially allowing B cells with higher affinities to acquire antigen and be selected, thus altering antibody production. With this mechanistic hypothesis, we performed stochastic simulations of the GC reaction, which recapitulated experiments, unravelled a quality-quantity trade-off constraining the GC response, and predicted passive immunization protocols that maximized the GC output.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Garg, A. K., Desikan, R., Dixit, N. M.. 2018-10-13. Stochastic simulations show how passive immunization can influence the germinal centre reaction and optimize host humoral responses. https://doi.org/10.1101/441691

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related preprints

CD19-CAR T-cell therapy resets the EBV+ autoreactive B cell repertoire in autoimmune disease

Epstein-Barr virus (EBV) reprograms autoreactive B cells into activated antigen-presenting cells that drive pathogenic T- and B-cell responses in autoimmune disease. Using EBV B-cell sequencing (EBV-seq), we profiled EBV+ B cells in patients treated with CD19 chimeric antigen receptor (CAR) T cells (systemic lupus, n=6; idiopathic inflammatory myopathies, n=3; systemic sclerosis, n=3) or rituximab (n=15). CAR T cells, but not rituximab, depleted EBV+ B cells, resetting the repertoire toward a naive state: predominantly IgM+ with minimal somatic hypermutation. Post-rituximab B-cells remained class-switched, hypermutated, and activated. Monoclonal antibodies cloned from EBV+ B cells lost autoreactivity after CAR T cells but not rituximab. Sustained drug-free remission occurred in 8/12 CAR-treated but 0/15 rituximab-treated patients. EBV+ B cells were predominantly Latency III and resisted anti-CD20 and anti-CD19 antibodies, yet were killed by CAR T cells and T-cell engagers. CD19-CAR T-cell therapy resets the autoreactive EBV+ B-cell repertoire, which may underlie sustained drug-free remission.

immunology↗

A minimal two-residue C-terminal truncation of AID in adult-onset hyper-IgM syndrome type 2 (HIGM2)

Activation-induced cytidine deaminase (AID), encoded by AICDA, facilitates class-switch recombination (CSR) and somatic hypermutation (SHM) in activated B cells. Loss of AID function causes hyper-IgM syndrome type 2 (HIGM2). While typically autosomal recessive, three C-terminal truncation variants have been reported to act in autosomal dominant manner. We describe a novel heterozygous AICDA nonsense variant, c.589G>T (p.G197*), that truncates the final two C-terminal residues of AID and results in adult-onset HIGM2. Single-cell sequencing of primary patient B cells revealed a complete block in CSR and a [~]10-fold reduction in SHM. AICDA mRNA expression was balanced between wild-type and variant alleles, yet AID protein abundance was reduced to [~]56% with normal subcellular localization. Remarkably, inducible germinal center (iGB) cultures restored CSR in purified naive patient B cells. CRISPR-Cas9 editing of healthy donor B cells confirmed that the iGB platform can rescue B cells harboring heterozygous, but not homozygous, AICDA variants. These results demonstrate that even a two-amino-acid truncation at the AID C-terminus is sufficient to disrupt its function and cause HIGM2.

immunology↗

Defining the Functional Consequence of the Human Ocular Microbiome

The ocular surface is one of the body's most environmentally exposed mucosal barriers, yet it is considered low biomass and harbors orders of magnitude fewer bacteria than microbe-rich sites like the gut. This has cast doubt on whether a functional core ocular microbiome exists at all. Having previously defined a protective gd T cell and IL-17 axis engaged by the murine commensal Corynebacterium mastitidis, we asked whether human-derived bacteria could do the same. Pairing sequencing and culturomics of healthy human conjunctiva from two geographically distinct cohorts, we define a stable core microbiome and identify Corynebacterium bovis as a consistent eye-resident commensal rather than a transient contaminant. In humans, C. bovis elicits a non-pathogenic response marked by IL-17 secretion by {gamma}{delta} T cells and circulating C. bovis-specific IgG, which suggests commensalism rather than pathology. Colonizing mice with human C. bovis strains from Pittsburgh or Miami reproduced this program and conferred protection against ocular infection with Staphylococcus aureus. Together, these findings identify C. bovis as a human-derived ocular commensal that can drive protective {gamma}{delta} T cell immunity, translating a mechanism previously defined only in mice into human relevance and a rational target against sight-threatening infection.

immunology↗